Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Expression of FGFR1-4 in malignant pleural mesothelioma tissue and corresponding cell lines and its relationship to patient survival and FGFR inhibitor sensitivity
Authors:ID Vlačić, Gregor, Klinika Golnik (Author)
ID Hoda, Mir Alireza (Author)
ID Klikovits, Thomas (Author)
ID Sinn, Katharina (Author)
ID Gschwandtner, Elisabeth (Author)
ID Mohorčič, Katja, Klinika Golnik (Author)
ID Schelch, Karin (Author)
ID Pirker, Christine (Author)
ID Peter-Vörösmarty, Barbara (Author)
ID Brankovic, Jelena (Author)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Author)
ID Rozman, Aleš, Klinika Golnik, Medicinska fakulteta UL (Author)
ID Kern, Izidor, Klinika Golnik (Author)
Files:.pdf PDF - Presentation file, download (1,74 MB)
MD5: F0416A5D8E35B3782493059018061316
 
URL URL - Source URL, visit https://www.mdpi.com/2073-4409/8/9/1091/pdf
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Malignant pleural mesothelioma (MPM) is a devastating malignancy with limited therapeutic options. Fibroblast growth factor receptors (FGFR) and their ligands were shown to contribute to MPM aggressiveness and it was suggested that subgroups of MPM patients could benefit from FGFR-targeted inhibitors. In the current investigation, we determined the expression of all four FGFRs (FGFR1-FGFR4) by immunohistochemistry in tissue samples from 94 MPM patients. From 13 of these patients, we were able to establish stable cell lines, which were subjected to FGFR1-4 staining, transcript analysis by quantitative RT-PCR, and treatment with the FGFR inhibitor infigratinib. While FGFR1 and FGFR2 were widely expressed in MPM tissue and cell lines, FGFR3 and FGFR4 showed more restricted expression. FGFR1 and FGFR2 showed no correlation with clinicopathologic data or patient survival, but presence of FGFR3 in 42% and of FGFR4 in 7% of patients correlated with shorter overall survival. Immunostaining in cell lines was more homogenous than in the corresponding tissue samples. Neither transcript nor protein expression of FGFR1-4 correlated with response to infigratinib treatment in MPM cell lines. We conclude that FGFR3 and FGFR4, but not FGFR1 or FGFR2, have prognostic significance in MPM and that FGFR expression is not suffcient to predict FGFR inhibitor response in MPM cell lines.
Keywords:malignant pleural mesothelioma, fibroblast growth factor receptors, azbestos, immunotherapy, chemotherapy, genomic analysis, infigratinib
Publication status:Published
Publication version:Version of Record
Place of publishing:Švica
Publisher:MDPI
Year of publishing:2019
Number of pages:str. 1-14
Numbering:Vol. 8, iss. 9
PID:20.500.12556/DiRROS-12527 New window
UDC:616-006
ISSN on article:2073-4409
DOI:10.3390/cells8091091 New window
COBISS.SI-ID:2048535409 New window
Copyright:© 2019 by the authors
Note:Soavtorji iz Slovenije: Katja Mohorcic, Tanja Cufer, Ales Rozman, Izidor Kern; Nasl. z nasl. zaslona; Opis vira z dne 17. 9. 2019; Št. prispevka: 1091;
Publication date in DiRROS:07.10.2020
Views:12790
Downloads:1326
Metadata:XML DC-XML DC-RDF
:
VLAČIĆ, Gregor, HODA, Mir Alireza, KLIKOVITS, Thomas, SINN, Katharina, GSCHWANDTNER, Elisabeth, MOHORČIČ, Katja, SCHELCH, Karin, PIRKER, Christine, PETER-VÖRÖSMARTY, Barbara, BRANKOVIC, Jelena, ČUFER, Tanja, ROZMAN, Aleš and KERN, Izidor, 2019, Expression of FGFR1-4 in malignant pleural mesothelioma tissue and corresponding cell lines and its relationship to patient survival and FGFR inhibitor sensitivity. Cells [online]. 2019. Vol. 8, no. 9, p. 1–14. [Accessed 1 April 2025]. DOI 10.3390/cells8091091. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=12527
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Cells
Shortened title:Cells
Publisher:MDPI
ISSN:2073-4409
COBISS.SI-ID:519958809 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:16.09.2019

Secondary language

Language:Undetermined
Keywords:maligni plevralni mezoteliom, receptorji za fibroblastne rastne dejavnike, azbest, imunoterapija, kemoterapija, genomska analiza, infigratinib


Back